Request Demo
Last update 27 Oct 2025
JYP-0322
Last update 27 Oct 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms JYP 0322, JYP-0322, JYP0322 |
Target |
Action inhibitors |
Mechanism ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with JYP-0322NCT07154368
A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of JYP0322 Versus Platinum-Based Chemotherapy in ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Previously Treated With ROS1-TKI Therapy.
NCT06128148
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors
CTR20253358
一项在既往接受 ROS1-TKI 治疗后的 ROS1 阳性局部晚期或转移性非小细胞肺癌患者中评价 JYP0322 对比含铂化疗的有效性和安全性的随机、开放、多中心、Ⅲ期研究
[Translation] A randomized, open-label, multicenter, phase III study evaluating the efficacy and safety of JYP0322 versus platinum-based chemotherapy in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer who have received prior ROS1-TKI therapy
100 Clinical Results associated with JYP-0322
Login to view more data
100 Translational Medicine associated with JYP-0322
Login to view more data
100 Patents (Medical) associated with JYP-0322
Login to view more data
100 Deals associated with JYP-0322
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Reactive oxygen species 1 positive non-small cell lung cancer | Phase 3 | China | 27 Aug 2025 | |
| Glioma | Phase 1 | China | 04 May 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 04 May 2022 | |
| ROS1 positive Solid Tumors | Phase 1 | China | 04 May 2022 | |
| ROS1 fusion positive Neoplasms | Phase 1 | China | 11 Apr 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NEWS Manual  | Not Applicable | 81 | (初治) | fgdzsnsytb(jauffbgjxr) = flweaewuaw vefyzrpghm (xumlvxtcvx ) View more | Positive | 07 May 2025 | |
(经治) | xnzacedkuy(boanwqbver) = rhgivetcsz eoyfacswlf (ywqxdnevth ) | ||||||
NCT06128148 (AACR2025) Manual | Phase 1 | 73 | (G2032R mutations) | ptlfkcuplt(zgcgbiiwkf) = wwojzplnup pzlevkpyct (pgjcjjxklq ) View more | Positive | 28 Apr 2025 | |
(G2032R mutations + Lorlatinib pretreated) | ptlfkcuplt(zgcgbiiwkf) = vkpaqhlkud pzlevkpyct (pgjcjjxklq ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free